Low testosterone diagnosis in Canada: what the rules require
Diagnosing low testosterone in Canada takes three things: symptoms, morning fasting blood testing, and a look at why the level is low. What testing your own case needs is a decision for your doctor or nurse practitioner. This page sets out what each guideline and Canadian product label says on the subject, with the date each was checked, so you can see what your prescriber is working from.
Key takeaways
- The Endocrine Society clinical practice guideline (Bhasin 2018, Journal of Clinical Endocrinology and Metabolism) requires symptoms plus consistently low morning fasting total testosterone, confirmed on repeat testing, together with an evaluation of the cause.
- The Canadian product monograph for oral testosterone undecanoate, authorized 12 December 2025, states the product should not be used to treat non-specific symptoms suggestive of hypogonadism if testosterone deficiency has not been demonstrated.
- Health Canada’s Information Update of 15 July 2014 advises that testosterone products should not be used for non-specific symptoms if laboratory tests have not confirmed a low level and other possible causes have not been excluded.
- The European Association of Urology guideline, 2026 edition with a limited update in March 2026, makes a strong recommendation for a total testosterone threshold of 12 nmol/L (3.5 ng/mL), measured fasting between 07:00 and 10:00 and confirmed on two separate occasions.
- Australia’s Pharmaceutical Benefits Scheme defines androgen deficiency for subsidy as testosterone below 6 nmol/L, or 6 to 15 nmol/L with a high LH, on at least two morning blood samples taken on different mornings.
- The European Academy of Andrology guideline of 2020 places lifestyle modification and weight reduction ahead of testosterone in functional hypogonadism, and requires organic causes to be excluded first.
Everything on this page describes men with confirmed low testosterone. It does not describe men whose testosterone is normal. That is the line every guideline and every Canadian label draws. What testing your own case needs is a decision for your doctor or nurse practitioner.
How is a low testosterone result confirmed?
That is a clinical decision, made by the doctor or nurse practitioner who is treating you, and it turns on your own history and results. What the published documents say is on the record and worth knowing.
The Endocrine Society clinical practice guideline (Bhasin 2018) asks for consistently low morning fasting total testosterone confirmed on repeat testing. The Canadian product monograph for oral testosterone undecanoate, authorized 12 December 2025, asks for two separate validated biochemical assays on morning testosterone. The European Association of Urology guideline, 2026 edition, asks for confirmation on two separate occasions, fasting, between 07:00 and 10:00. Australia’s Pharmaceutical Benefits Scheme asks for at least two morning samples drawn on different mornings.
Trials use the same standard. TRAVERSE, published in the New England Journal of Medicine in 2023, enrolled 5,246 men aged 45 to 80 who had hypogonadal symptoms and two fasting testosterone levels below 300 ng/dL. Entry criteria matter when reading what testosterone therapy actually does, because the results apply only to men who met them.
What does the Endocrine Society guideline require?
Three things: symptoms, biochemistry and a cause. The Endocrine Society clinical practice guideline on testosterone therapy in men with hypogonadism (Bhasin 2018, Journal of Clinical Endocrinology and Metabolism 103(5):1715-1744) recommends testosterone therapy for men with symptomatic testosterone deficiency, to induce and maintain secondary sex characteristics and to correct symptoms of hypogonadism.
Its diagnostic requirement is symptoms plus consistently low morning fasting total testosterone, confirmed on repeat testing, plus evaluation of the cause. The third element is the one most often skipped. A low reading is a finding, not a diagnosis, until something has been done to establish why it is low.
What does the Canadian product monograph require?
The Canadian labels set the legally approved wording, and they are specific. The product monograph for oral testosterone undecanoate capsules, authorized 12 December 2025, carries the indication “indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (male hypogonadism).”
Before treatment, that monograph requires deficiency to be “clearly demonstrated by clinical features and confirmed by two separate validated biochemical assays (morning testosterone).” It also states that the product should not be used “to treat non-specific symptoms suggestive of hypogonadism if testosterone deficiency has not been demonstrated.” Safety and efficacy for age-related hypogonadism are not established in that monograph, its warnings cover blood pressure increases and venous thromboembolism, and it carries no boxed warning.
The older Canadian monograph for testosterone cypionate, revised 12 July 2018, uses the same indication wording and advises cardiovascular risk assessment before starting.
What has Health Canada said about testing before treatment?
Health Canada’s position dates from 2014 and has not been revised. Its Summary Safety Review on testosterone replacement products and cardiovascular risk, dated 15 July 2014, reviewed 35 Canadian reports of cardiovascular problems received to 31 August 2013, concluded that post-market studies suggest an increased risk of serious cardiovascular problems that may be linked to testosterone products, and committed to label updates.
The Information Update issued the same day, 15 July 2014, advises that testosterone products should not be used in men for non-specific symptoms if laboratory tests have not been done to confirm a low testosterone level and other possible causes for the symptoms have not been excluded.
Health Canada has issued nothing further on testosterone since July 2014. There is no Canadian regulatory response to TRAVERSE or to either of the American label changes that followed it. That gap is set out in detail in the comparison of how Canada’s testosterone rules differ from the US, Europe and Australia.
What testosterone level counts as low?
There is no single number that all bodies agree on, and Canada’s labels do not print one. The table below sets out what each body actually specifies, with the date of the document it comes from.
| Body and document | Date | Threshold specified | Timing and repeat requirement |
|---|---|---|---|
| Endocrine Society clinical practice guideline (Bhasin 2018) | 2018 | No numeric cut-off in the text used here; requires consistently low total testosterone | Morning, fasting, confirmed on repeat testing, plus evaluation of the cause |
| Canadian product monograph, oral testosterone undecanoate | Authorized 12 December 2025 | No numeric cut-off stated | Two separate validated biochemical assays on morning testosterone, plus clinical features |
| European Association of Urology guideline, male hypogonadism chapter | 2026 edition, limited update March 2026 | 12 nmol/L total testosterone (3.5 ng/mL), strong recommendation | Fasting, between 07:00 and 10:00, confirmed on two separate occasions |
| Australian Pharmaceutical Benefits Scheme, item 10205D | Schedule retrieved 13 September 2026 | Below 6 nmol/L, or 6 to 15 nmol/L with high LH | At least two morning blood samples on different mornings; patient 40 or older on the non-organic pathway |
| TRAVERSE trial entry criterion (Lincoff 2023) | 2023 | Below 300 ng/dL | Two fasting measurements, plus hypogonadal symptoms |
Where does the 12 nmol/L figure come from?
It comes from the older meta-analytic literature. Isidori 2005, in Clinical Endocrinology, pooled 17 randomized placebo-controlled trials in 656 subjects and found that in men with baseline testosterone below 12 nmol/L, treatment moderately improved nocturnal erections, sexual thoughts and motivation, successful intercourse, erectile function scores and overall sexual satisfaction. The same analysis found no effect in eugonadal men, that is, men whose testosterone was already normal.
Corona 2017, in European Urology, pooled 14 placebo-controlled randomized trials in 2,298 participants with a mean age of 60.2 years and a mean follow-up of 40.1 weeks. It found a mean improvement of 1.47 points (95% CI 0.90 to 2.03) on the erectile function domain in men below 12 nmol/L, and 2.95 points (95% CI 1.86 to 4.03) in men below 8 nmol/L. The threshold marks a gradient, not a switch. More detail sits in the review of testosterone and erectile function.
What if the low reading has an obvious cause?
Then the cause is addressed first. The European Academy of Andrology guideline on functional hypogonadism in males, published in Andrology in 2020, recognizes that testosterone therapy can reliably improve global sexual function in men with hypogonadism in the short term. For functional, meaning non-organic, hypogonadism, the same guideline puts lifestyle modification and weight reduction ahead of testosterone, and requires organic causes to be excluded.
How does Australia define it, and why does the contrast matter?
Australia writes the exclusions into a funding rule, which no other jurisdiction here does. The Pharmaceutical Benefits Scheme listing for testosterone undecanoate, item 10205D, retrieved 13 September 2026, has two Authority Required pathways for androgen deficiency.
Where there is an established pituitary or testicular disorder, treatment must be by or in consultation with a specialist endocrinologist, urologist, pediatrician or Fellow of the Australasian Chapter of Sexual Health Medicine. Where there is no established organic disease, the patient must be 40 or older, the condition must not be due to age, obesity, cardiovascular diseases, infertility or drugs, and androgen deficiency is defined as testosterone below 6 nmol/L, or 6 to 15 nmol/L with a high LH (above 1.5 times the upper limit of the young-men reference range, or above 14 IU/L, whichever is higher), confirmed on at least two morning blood samples on different mornings.
Canada has no equivalent national rule. The Canadian requirement lives in the product monographs and in the 2014 Health Canada advice, not in a funding criterion.
Who should not start testosterone therapy?
Two bodies publish lists, and they overlap. The Endocrine Society clinical practice guideline (Bhasin 2018) recommends against starting testosterone in men who are:
- planning fertility in the near term
- diagnosed with breast cancer or prostate cancer
- found to have a palpable prostate nodule
- found to have a PSA above 4 ng/mL, or above 3 in men at increased risk, without urological evaluation
- found to have an elevated hematocrit
- affected by untreated severe obstructive sleep apnea
- affected by severe lower urinary tract symptoms
- living with uncontrolled heart failure
- within six months of a myocardial infarction or stroke
- diagnosed with thrombophilia
The European Association of Urology guideline, 2026 edition with a limited update in March 2026, lists as contraindications locally advanced or metastatic prostate cancer, male breast cancer, an active desire to father children, a hematocrit of 54 percent or above, and uncontrolled congestive heart failure. The same guideline sets monitoring at 3, 6 and 12 months, then annually, which is covered in the page on monitoring during testosterone therapy in Canada.
What the evidence does not show
A diagnostic threshold is a rule for starting a conversation, not a prediction of who will improve. Several findings make that clear, and they should be read alongside the thresholds above.
- No baseline level reliably predicted response in older men. Cunningham 2016, in the Journal of Clinical Endocrinology and Metabolism, reported on 470 men aged 65 and older across 12 American academic centres. Testosterone significantly improved 10 of 12 measures of sexual activity, but no threshold testosterone level predicted response, and none of 27 baseline characteristics predicted who would respond.
- The guidelines disagree with each other on whether depth of deficiency matters. Corona 2017 found a larger erectile function effect in men below 8 nmol/L than in men below 12 nmol/L. Hudson 2023, in Lancet Healthy Longevity, drawing on 35 studies and 5,601 participants with individual participant data from 17 trials covering 3,431 men at a median age of 67, found the symptomatic benefit was not dependent on age, obesity, diabetes or how low the baseline testosterone was. Both results stand; neither has been resolved by a purpose-built trial.
- No benefit has been shown in men with normal testosterone. Isidori 2005 found no effect in eugonadal men, and no regulator or guideline cited on this page supports treating a man whose confirmed levels are normal.
- Canada has published no threshold. The Canadian monographs require deficiency to be demonstrated and confirmed, but they do not print a number, so the laboratory reference range and the clinician’s judgement carry that decision.
Frequently asked questions
Can low testosterone be diagnosed from one blood test?
No. The Endocrine Society clinical practice guideline (Bhasin 2018) requires consistently low morning fasting total testosterone confirmed on repeat testing. The Canadian product monograph for oral testosterone undecanoate, authorized 12 December 2025, requires two separate validated biochemical assays on morning testosterone. The European Association of Urology guideline, 2026 edition, requires confirmation on two separate occasions.
What time of day should the blood test be taken?
The European Association of Urology guideline, 2026 edition with a limited update in March 2026, specifies a fasting sample drawn between 07:00 and 10:00, confirmed on two separate occasions. The Canadian product monograph for oral testosterone undecanoate, authorized 12 December 2025, specifies morning testosterone. Australia’s Pharmaceutical Benefits Scheme requires at least two morning blood samples taken on different mornings.
Is 12 nmol/L the official Canadian cut-off?
No. The 12 nmol/L figure (3.5 ng/mL) is a strong recommendation of the European Association of Urology guideline, 2026 edition, not a Health Canada number. The Canadian monographs require deficiency to be clearly demonstrated by clinical features and confirmed by two separate validated biochemical assays, without printing a threshold. Ask your doctor or pharmacist which laboratory reference range applies to your result.
Does tiredness on its own mean low testosterone?
No. Health Canada’s Information Update of 15 July 2014 advises that testosterone products should not be used in men for non-specific symptoms if laboratory tests have not been done to confirm a low testosterone level and other possible causes have not been excluded. The Canadian product monograph authorized 12 December 2025 repeats that point for non-specific symptoms suggestive of hypogonadism.
What happens if the low level is caused by weight or illness?
The European Academy of Andrology guideline of 2020 on functional hypogonadism places lifestyle modification and weight reduction first, and requires organic causes to be excluded before testosterone is considered. Australia’s Pharmaceutical Benefits Scheme goes further on its non-organic pathway: the deficiency must not be due to age, obesity, cardiovascular diseases, infertility or drugs.
Who should not start testosterone therapy?
The Endocrine Society clinical practice guideline (Bhasin 2018) recommends against starting in men planning fertility in the near term, men with breast or prostate cancer, a palpable prostate nodule, a PSA above 4 ng/mL without urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, a myocardial infarction or stroke in the last six months, or thrombophilia.
Do these findings apply to men whose testosterone is normal?
No. Every figure on this page comes from men with confirmed low testosterone. Isidori 2005, in Clinical Endocrinology, pooling 17 randomized placebo-controlled trials in 656 subjects, found no effect in eugonadal men, meaning men whose testosterone is already within the normal range.
References
- Bhasin 2018. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism 103(5):1715-1744. PMID 29562364. DOI: https://doi.org/10.1210/jc.2018-00229
- Isidori 2005. Effects of testosterone on sexual function in men: results of a meta-analysis. Clinical Endocrinology. PMID 16181230. DOI: https://doi.org/10.1111/j.1365-2265.2005.02350.x
- Corona 2017. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. European Urology. PMID 28434676. DOI: https://doi.org/10.1016/j.eururo.2017.03.032
- Cunningham 2016. Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels. Journal of Clinical Endocrinology and Metabolism. PMID 27355400. DOI: https://doi.org/10.1210/jc.2016-1645
- Hudson 2023. Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis. Lancet Healthy Longevity. PMID 37804846. DOI: https://doi.org/10.1016/S2666-7568(23)00169-1
- Lincoff 2023. Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine. PMID 37326322. DOI: https://doi.org/10.1056/NEJMoa2215025
- European Academy of Andrology. Guidelines on functional hypogonadism in males. Andrology 2020;8(5):970-987. DOI: https://doi.org/10.1111/andr.12770
- Health Canada. Summary Safety Review, Testosterone Replacement Products, Cardiovascular Risk. 15 July 2014. https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00058
- Health Canada. Information Update, Possible cardiovascular problems associated with testosterone products. 15 July 2014. https://recalls-rappels.canada.ca/en/alert-recall/information-update-possible-cardiovascular-problems-associated-testosterone-products
- Health Canada. Product Monograph, JATENZO (testosterone undecanoate oral capsules). Authorized 12 December 2025. https://pdf.hres.ca/dpd_pm/00082762.PDF
- Health Canada. Product Monograph, DEPO-TESTOSTERONE (testosterone cypionate). Revised 12 July 2018. https://pdf.hres.ca/dpd_pm/00046306.PDF
- European Association of Urology. Guidelines on Sexual and Reproductive Health, male hypogonadism chapter. 2026 edition, limited update March 2026. https://uroweb.org/guidelines/sexual-and-reproductive-health/chapter/male-hypogonadism
- Pharmaceutical Benefits Scheme, Australia. Testosterone undecanoate, item 10205D. Schedule retrieved 13 September 2026. https://www.pbs.gov.au/medicine/item/10205D
This page is educational information, not medical advice. Testosterone is a prescription medication and a controlled substance in Canada. Talk to your doctor or pharmacist about your own situation.